Figure 1 | Scientific Reports

Figure 1

From: Intraperitoneal Administration of a Novel TAT-BDNF Peptide Ameliorates Cognitive Impairments via Modulating Multiple Pathways in Two Alzheimer’s Rodent Models

Figure 1

Intraperitoneal administration of the TAT-BDNF fusion peptide improves memory deficits in APPswe mice and scopolamine-induced rats.

APPswe mice (12 month old) (n = 10) (A–E) or SD rats (n = 10) (F–J) were injected respectively via intraperitoneal with saline (vehicle control), or TAT (vector control), or TAT-BDNF (PEP, 0.16 μg/day and 1.6 μg/day for one week in rats, 2.4 μg/day for one month in mice). The spatial learning and memory were measured by water maze test. The age-matched wild type littermates were used as naïve control of APPswe. To produce AD-like cholinergic dysfunction model, scopolamine (Sco, 1 mg/kg) was injected through peritoneal 0.5 h before the behavior test. The scrambled TAT-BDNF (Scp, 1.6 μg/day) and galantamine (Gal, 3.0 mg/kg) were used respectively as negative and positive controls. *p < 0.05, **p < 0.01 vs Con (APPwt or normal rats), #p < 0.05, ##p < 0.01 vs APPswe group.

Back to article page